Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
May 15 ADAP Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
May 15 ATNM Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
May 15 ADAP Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M
May 15 ADAP Adaptimmune Therapeutics gets $125M in financing from Hercules Capital
May 15 ADAP Adaptimmune Reports Q1 2024 Financial and Business Updates
May 15 ADAP Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
May 15 ABOS Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 15 ABOS Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
May 15 APTO Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
May 14 ATNM Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the ...
May 14 APTO Aptose Biosciences GAAP EPS of -$0.73 beats by $0.09
May 14 APTO Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses
May 14 APTO Aptose Reports Results for the First Quarter 2024
May 14 ADAP Adaptimmune Q1 2024 Earnings Preview
May 14 ABOS Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
May 14 ABOS Acumen Pharmaceuticals GAAP EPS of -$0.25
May 14 ABOS Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 13 ABOS Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13 BRNS Barinthus Biotherapeutics GAAP EPS of -$0.40
May 13 ATNM Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags